Anacetrapib

Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
MK0859
Fluorinated Building Blocks, API&Intermediates
KAPI10F01
875446-37-0
MFCD16294903
11556427
11332484
image-155171-Trimethyl(trifluoromethyl)silane_reagent.png
Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Anacetrapib
C30H25F10NO3
637.52
≥99%
White Solid
70-73°C
500mg,1g,2g,5g,10g,25g,50g and 100g
Store at -20°C temp.
Anacetrapib (also known as MK0859) is a potent and selective cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis, in particular dyslipidemia.
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. [1]
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. [2]
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. [3]
Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subject. [4]
Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. [5]
Cholesteryl Ester Transfer Protein (CETP) Deficiency and CETP Inhibitors. [6]
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. [7]
Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice. [8]
References:
[1] R.Krishna, et al, Clin. Pharmacol. Ther., 2008, 84(6), pp 679-683.
[2] R.Krishna, et al, Br. J. Clin. Pharmacol., 2009, 68(4), pp 535-545.
[3] S.Kumar, et al, Drug Metab. Dispos., 2010, 38(3), pp 474-483.
[4] A.Garg, et al, J. Clin. Pharmacol., 2011, 51(3), pp 436-439.
[5] J.Castro-perez, et al, J. Lipid Res., 2011, 52(11), pp 1965-1973.
[6] H.Mabuchi, et al, Mol. Cells, 2014, 37(11), pp 777-784.
[7] S.J.Van Der Tuin, et al, J. Liqid Res., 2015, 56(11), pp 2085-2093.
[8] G.Hartmann, et al, Drug Metab. Dispos., 2016, 44(3), pp 428-434.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Warning
H317,H319
P261,P264,P272,P280,P302+P352,P305+P351+P338,P333+P313,P337+P313

NONH for all modes of transport

1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.